July is proving to be an exciting month here in the UK. Andy Murray is the new Wimbledon Champion, we’re enjoying lots of wonderful warm weather and we’re anticipating the arrival of the new royal baby. But before the Duke and Duchess of Cambridge have news for us, we have news for them, for these are exciting times too in the world of Cochrane and yesterday saw the publication of new evidence that delaying clamping the cord after birth benefits babies.
In many high-income countries it is usual to clamp the baby’s cord within a minute of birth, which may reduce the amount of blood that passes from mum to baby, affecting the baby’s iron stores. On the other hand, delaying cord clamping may slightly increase the risk of jaundice. A newly updated Cochrane review has assessed the effect of the timing of cord clamping in fifteen Clinical trials are research studies involving people who use healthcare services. They often compare a new or different treatment with the best treatment currently available. This is to test whether the new or different treatment is safe, effective and any better than what is currently used. No matter how promising a new treatment may appear during tests in a laboratory, it must go through clinical trials before its benefits and risks can really be known. with almost 4000 women and their babies. The overall The certainty (or quality) of evidence is the extent to which we can be confident that what the research tells us about a particular treatment effect is likely to be accurate. Concerns about factors such as bias can reduce the certainty of the evidence. Evidence may be of high certainty; moderate certainty; low certainty or very-low certainty. Cochrane has adopted the GRADE approach (Grading of Recommendations Assessment, Development and Evaluation) for assessing certainty (or quality) of evidence. Find out more here: https://training.cochrane.org/grade-approach was moderate to high. Clamping the cord later made no difference to the mums’ iron levels or blood loss but it was good for babies, who had higher haemoglobin levels one to two days after birth and were less likely to be short of iron three to six months later. They also had higher birth weights. More babies for whom cord clamping was delayed had jaundice. The reviewers concluded that delayed cord clamping is likely to be beneficial as long as access to Something done with the aim of improving health or relieving suffering. For example, medicines, surgery, psychological and physical therapies, diet and exercise changes. for jaundice needing light therapy is available.
One of the review authors, Philippa Middleton (there’s a coincidence!), commented in a press release that in the light of the available evidence “a more liberal approach to delaying clamping of the umbilical cord in healthy babies appears to be warranted” and that “later cord clamping to increase iron stores may be particularly beneficial in settings where severe anaemia is common”. Another Cochrane review on the effect of timing of cord clamping and other strategies, updated with the addition of 33 studies in 2017, found that “delayed, rather than early, cord clamping may reduce the A way of expressing the chance of an event taking place, expressed as the number of events divided by the total number of observations or people. It can be stated as ‘the chance of falling were one in four’ (1/4 = 25%). This measure is good no matter the incidence of events i.e. common or infrequent. of death before discharge for babies born preterm. There is insufficient evidence to show what duration of delay is best, one or several minutes, and therefore the optimum time to clamp the umbilical cord remains unclear”.
Before we move away from the subject of babies, I’ll flag up an important update to a review on intravenous immunoglobulin (IVIG) for suspected or proven infection in neonates. In earlier versions of the review, the authors highlighted the need for good trials looking at whether IVIG improves outcomes for these babies and one large, high quality trial has now been done and is included in the review. The INIS trial, with almost 3500 infants, found no reduction in death or major disability at two years in babies treated with IVIG and the reviewers judge these results to be ‘unequivocal’, with no further research needed. The review of IVIG for preventing infection in preterm and low birth weight babies has also been updated but with no new studies to add. IVIG offers a very small reduction in infection but it doesn’t cut the length of time spent in hospital or appear to confer any benefit in terms of other A result (e.g. a treatment effect) that is large enough to be important to patients and healthcare providers. This is not the same thing as statistically significant. Assessing clinical significance takes into account factors such as the size of a treatment effect, the severity of the condition being treated, the side effects of the treatment, and the cost. For instance, showing that a drug lowered the heart rate by an average of 1 beat per minute would not be clinically significant. Outcomes are measures of health (for example quality of life, pain, blood sugar levels) that can be used to assess the effectiveness and safety of a treatment or other intervention (for example a drug, surgery, or exercise). In research, the outcomes considered most important are ‘primary outcomes’ and those considered less important are ‘secondary outcomes’., including death.
Many of you not giving birth this summer may be looking ahead to holidays or work trips abroad and will be hoping to avoid ‘travellers diarrhoea’. Enterotoxigenic Escherichia coli bacteria (ETEC) is a major cause of this and can be passed on through drinking unclean water or food. It’s similar to the bacteria that causes cholera and a new review has looked at whether vaccines to prevent ETEC infections or to prevent cholera are effective in preventing diarrhoea caused by ETEC. Twenty-four randomized A trial in which a group (the ‘intervention group’) is given a intervention being tested (for example a drug, surgery, or exercise) is compared with a group which does not receive the intervention (the ‘control group’). with over 52,000 people were included, but they were rather a mixed bag and at present there isn’t enough evidence to support the use of oral cholera vaccine Dukoral® for protecting travellers against ETEC diarrhoea. The reviewers say that further work needs to be done on developing safe and effective vaccines. Staycation anyone?
You can’t make a silk purse out of a sow’s ear and whilst the valiant team of reviewers at the Stroke Group made various improvements to their review on cognitive rehabilitation for spatial neglect following stroke for its latest update, including adding a number of secondary Outcomes are measures of health (for example quality of life, pain, blood sugar levels) that can be used to assess the effectiveness and safety of a treatment or other intervention (for example a drug, surgery, or exercise). In research, the outcomes considered most important are ‘primary outcomes’ and those considered less important are ‘secondary outcomes’. which had been identified as being important to people after stroke, the evidence remains too poor to say whether or not cognitive rehabilitation is helpful. The authors say that the emerging evidence does justify further Clinical trials are research studies involving people who use healthcare services. They often compare a new or different treatment with the best treatment currently available. This is to test whether the new or different treatment is safe, effective and any better than what is currently used. No matter how promising a new treatment may appear during tests in a laboratory, it must go through clinical trials before its benefits and risks can really be known., but well designed and properly reported ones please.
I’ll be bringing you another round-up in a fortnight to give you some more gems from the Cochrane Library but before that I’ll be looking at a review or two in more depth. Gems and silk purses may well be amongst the gifts soon to be showered on newborn HRH (rather ironic that we await a major royal delivery just as plans are announced to sell off the Royal Mail) but I think a knitted hat with the Cochrane logo on the top would be just the thing. If you haven’t read the story of our logo, you can do so here. It beautifully illustrates how the evidence from good In systematic reviews we search for and summarize studies that answer a specific research question (e.g. is paracetamol effective and safe for treating back pain?). The studies are identified, assessed, and summarized by using a systematic and predefined approach. They inform recommendations for healthcare and research. can save lives.
References may be found here.
Sarah Chapman has nothing to disclose.
Page last updated: 18 September 2019